|
Group
|
Total number of rats
|
Number of rats with tumor
|
Incidence (%)
|
Multiplicity (average number/rat)
|
Latency (days)
|
Final body weight (g)
|
|---|
|
No treatment
|
8
|
0
|
0
|
-
|
-
|
291.3 ± 5.2
|
|
MNU only
|
14
|
13
|
92.8
|
2.6 ± 0.6
|
74.4 ± 7.1
|
281.7 ± 4.8
|
|
MNU + 10 mg/kg 3,6-DHF
|
14
|
9
|
64.3
|
2.2 ± 0.3
|
80.8 ± 7.8
|
275.5 ± 5.8
|
|
MNU + 20 mg/kg 3,6-DHF
|
14
|
8*
|
57.1*
|
1.9 ± 0.4*
|
87.5 ± 5.1**
|
278.7 ± 5.1
|
- Data presented as mean ± standard deviation. *P < 0.05, **P < 0.01 compared with the 1-methyl-1-nitrosourea (MNU)-only treatment group. Tumor incidence in the MNU + 20 mg/kg 3,6-dihydroxyflavone (3,6-DHF) treatment group was significantly lower than that in the MNU-only treatment group, indicating that oral administration of 3,6-DHF (20 mg/kg/day) can effectively suppress MUN-induced mammal carcinogenesis.
